CTX-009 + CTX-471 for Glioblastoma

This trial tests two treatments, CTX-009 and CTX-471, to determine if they can better control and extend the lives of people with recurrent glioblastoma, an aggressive brain tumor. CTX-009 aims to improve current treatments by targeting tumor resistance to existing drugs, while CTX-471 seeks to enhance the body's immune response against the tumor. The trial consists of two parts: one tests CTX-009 alone, and the other tests the combination of both drugs. Ideal candidates for this trial are individuals with recurrent glioblastoma after standard treatments like surgery, chemotherapy, or radiation, who manage their symptoms with stable doses of medications such as steroids or anti-seizure drugs. As a Phase 1 trial, this research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

The trial requires a stable or decreasing dose of corticosteroids and anti-seizure medications for 7 days before starting the study drugs. You must also stop using aspirin, NSAIDs, or other antiplatelet agents 7 days before starting the study drugs. If you are on full-dose anticoagulants, you need to stop them 7 days before starting the study drugs, but low-dose anticoagulants for device patency are allowed.

Research has shown that CTX-009, whether used alone or with CTX-471, has been tested in several studies. When combined with treatments like paclitaxel, CTX-009 has produced side effects similar to those expected from earlier research. Initial studies on CTX-471 have involved patients with various types of cancer to understand the drug's mechanism and potential side effects.

As this trial is in its early stages, the main focus is on safety. Researchers are still learning about the treatment's effects and how well participants can tolerate it. Participants are closely monitored for any unwanted effects, which helps gather more safety information.

Researchers are excited about the treatments CTX-009 and CTX-471 for glioblastoma because they offer a novel approach compared to standard therapies like surgery, radiation, and temozolomide chemotherapy. CTX-009 is unique because it targets specific pathways that may be more effective at shutting down tumor growth than traditional methods. Additionally, the combination with CTX-471 introduces a new mechanism by potentially enhancing the immune system's ability to fight cancer, something current treatments don’t specifically address. This dual approach could lead to better outcomes for patients with this aggressive brain cancer.

Research has shown that CTX-009 has potential in treating certain cancers, such as biliary tract cancer, with a 37.5% response rate when combined with another drug. In this trial, some participants will receive CTX-009 as monotherapy. Early studies have demonstrated that CTX-471, on its own, helps the immune system attack tumors effectively. Other participants in this trial will receive a combination of CTX-009 and CTX-471. This combination might enhance effectiveness by improving tumor control and boosting the local immune response. These effects could help manage tumor growth and increase survival in patients with recurring glioblastoma.¹⁶⁷⁸⁹